257 related articles for article (PubMed ID: 38137547)
1. CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy.
Nip C; Wang L; Liu C
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137547
[TBL] [Abstract][Full Text] [Related]
2. CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.
Liu JQ; Hu A; Zhu J; Yu J; Talebian F; Bai XF
Adv Exp Med Biol; 2020; 1223():155-165. PubMed ID: 32030689
[TBL] [Abstract][Full Text] [Related]
3. CD200 Blockade Modulates Tumor Immune Microenvironment but Fails to Show Efficacy in Inhibiting Tumor Growth in a Murine Model of Melanoma.
Talebian F; Yu J; Lynch K; Liu JQ; Carson WE; Bai XF
Front Cell Dev Biol; 2021; 9():739816. PubMed ID: 34692697
[TBL] [Abstract][Full Text] [Related]
4. Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade.
Choe D; Choi D
Front Oncol; 2023; 13():1088038. PubMed ID: 36756156
[TBL] [Abstract][Full Text] [Related]
5. CD200R signaling contributes to unfavorable tumor microenvironment through regulating production of chemokines by tumor-associated myeloid cells.
Lin CH; Talebian F; Li Y; Zhu J; Liu JQ; Zhao B; Basu S; Pan X; Chen X; Yan P; Carson WE; Xin G; Wen H; Wang R; Li Z; Ma Q; Bai XF
iScience; 2023 Jun; 26(6):106904. PubMed ID: 37275530
[TBL] [Abstract][Full Text] [Related]
6. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
[TBL] [Abstract][Full Text] [Related]
7. Different mechanisms of CD200-CD200R induce diverse outcomes in cancer treatment.
Liao KL; Watt KD; Protin T
Math Biosci; 2023 Nov; 365():109072. PubMed ID: 37734537
[TBL] [Abstract][Full Text] [Related]
8. The CD200-CD200R Axis Promotes Squamous Cell Carcinoma Metastasis via Regulation of Cathepsin K.
Khan IZ; Del Guzzo CA; Shao A; Cho J; Du R; Cohen AO; Owens DM
Cancer Res; 2021 Oct; 81(19):5021-5032. PubMed ID: 34183355
[TBL] [Abstract][Full Text] [Related]
9. Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes.
Najar M; Raicevic G; Jebbawi F; De Bruyn C; Meuleman N; Bron D; Toungouz M; Lagneaux L
Immunol Lett; 2012 Aug; 146(1-2):50-6. PubMed ID: 22575528
[TBL] [Abstract][Full Text] [Related]
10. A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma.
Liu JQ; Talebian F; Wu L; Liu Z; Li MS; Wu L; Zhu J; Markowitz J; Carson WE; Basu S; Bai XF
J Immunol; 2016 Aug; 197(4):1489-97. PubMed ID: 27385779
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer.
Vathiotis IA; MacNeil T; Zugazagoitia J; Syrigos KN; Aung TN; Gruver AM; Vaillancourt P; Hughes I; Hinton S; Driscoll K; Rimm DL
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33804482
[TBL] [Abstract][Full Text] [Related]
12. The role of CD200-CD200R in tumor immune evasion.
Liao KL; Bai XF; Friedman A
J Theor Biol; 2013 Jul; 328():65-76. PubMed ID: 23541619
[TBL] [Abstract][Full Text] [Related]
13. The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy.
Shao A; Owens DM
Oncotarget; 2023 Feb; 14():96-103. PubMed ID: 36738455
[TBL] [Abstract][Full Text] [Related]
14. The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies.
Pilch Z; Tonecka K; Skorzynski M; Sas Z; Braniewska A; Kryczka T; Boon L; Golab J; Meyaard L; Rygiel TP
PLoS One; 2019; 14(1):e0210796. PubMed ID: 30653571
[TBL] [Abstract][Full Text] [Related]
15. CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment.
Xin C; Zhu J; Gu S; Yin M; Ma J; Pan C; Tang J; Zhang P; Liu Y; Bai XF; Mo X; Xu M; Zhu H
Cancer Immunol Immunother; 2020 Nov; 69(11):2333-2343. PubMed ID: 32514618
[TBL] [Abstract][Full Text] [Related]
16. CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinoma.
Sun H; Xu J; Huang M; Huang Q; Sun R; Xiao W; Sun C
Immunol Lett; 2016 Oct; 178():105-13. PubMed ID: 27562325
[TBL] [Abstract][Full Text] [Related]
17. CD200-CD200R affects cisplatin and paclitaxel sensitivity by regulating cathepsin K-mediated p65 NF-κB signaling in cervical cancer.
Mou J; Zheng W; Wei D; Li D; Fan R; Tang Q
Heliyon; 2023 Aug; 9(8):e19220. PubMed ID: 37654464
[TBL] [Abstract][Full Text] [Related]
18. CD200-CD200R signaling and diseases: a potential therapeutic target?
Ngwa C; Liu F
Int J Physiol Pathophysiol Pharmacol; 2019; 11(6):297-309. PubMed ID: 31993106
[TBL] [Abstract][Full Text] [Related]
19. Cellular distribution of CD200 receptor in rats and its interaction with cytomegalovirus e127 protein.
El-Mokhtar MA; Bauer A; Madela J; Voigt S
Med Microbiol Immunol; 2018 Nov; 207(5-6):307-318. PubMed ID: 30032349
[TBL] [Abstract][Full Text] [Related]
20. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.
Moertel CL; Xia J; LaRue R; Waldron NN; Andersen BM; Prins RM; Okada H; Donson AM; Foreman NK; Hunt MA; Pennell CA; Olin MR
J Immunother Cancer; 2014; 2(1):46. PubMed ID: 25598973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
